Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cytokinetics and Bayer Announce €70 Million Collaboration for Aficamten Development in Japan to Treat Hypertrophic Cardiomyopathy Quiver Quantitative, Inc. - Tue Nov 19, 11:44AM CST

Cytokinetics and Bayer partner to develop aficamten for hypertrophic cardiomyopathy in Japan, involving substantial payments and milestone incentives.Quiver AI SummaryCytokinetics and Bayer have announced...

CYTK : 51.00 (+2.29%)
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan GlobeNewswire - Tue Nov 19, 1:30AM CST

CYTK : 51.00 (+2.29%)
Cytokinetics Presents New Data on Omecamtiv Mecarbil from GALACTIC-HF Trial at AHA Scientific Sessions 2024 Quiver Quantitative, Inc. - Sat Nov 16, 6:24PM CST

Cytokinetics presented new analyses on omecamtiv mecarbil's efficacy in heart failure at the AHA Scientific Sessions 2024.Quiver AI SummaryCytokinetics, Incorporated announced new findings from post-hoc...

CYTK : 51.00 (+2.29%)
Cytokinetics Presents Promising New Data on Aficamten for Hypertrophic Cardiomyopathy at AHA Scientific Sessions 2024 Quiver Quantitative, Inc. - Sat Nov 16, 6:24PM CST

New analyses show Aficamten improves oxygen uptake recovery, quality of life, and reduces septal reduction therapy eligibility in HCM patients.Quiver AI SummaryCytokinetics, Incorporated announced new...

CYTK : 51.00 (+2.29%)
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 GlobeNewswire - Sat Nov 16, 8:00AM CST

CYTK : 51.00 (+2.29%)
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 GlobeNewswire - Sat Nov 16, 8:00AM CST

CYTK : 51.00 (+2.29%)
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference GlobeNewswire - Tue Nov 12, 3:00PM CST

CYTK : 51.00 (+2.29%)
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089 GlobeNewswire - Mon Nov 11, 6:30AM CST

CYTK : 51.00 (+2.29%)
Cytokinetics: Q3 Earnings Snapshot AP - Wed Nov 6, 3:06PM CST

Cytokinetics: Q3 Earnings Snapshot

CYTK : 51.00 (+2.29%)
Cytokinetics Reports Third Quarter 2024 Financial Results GlobeNewswire - Wed Nov 6, 3:00PM CST

CYTK : 51.00 (+2.29%)

Barchart Exclusives

Is Palo Alto Networks Stock a Buy or Sell? Barchart - 15 minutes ago
Palo Alto delivered better-than-expected revenue and profitability in Q1, and the cybersecurity giant even raised its full-year guidance. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot